February 14, 2018 / 1:53 PM / 2 months ago

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

Reuters Staff

1 Min Read

Feb 14 (Reuters) - Myokardia Inc:

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

* MYOKARDIA INC - TOPLINE RESULTS FROM PHASE 1B STUDY OF MYK-491 ARE ANTICIPATED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.